ActiTrexx

ActiTrexx is a clinical-stage biotechnology company based in Mainz, Germany, specializing in the development of innovative regulatory T cell (Treg) therapies. The company was founded in 2020 as a spin-off from the University Medical Center Mainz to commercialize a proprietary method for activating and optimizing Tregs ex vivo. Its lead product candidate, ATX-101, is an autologous cell therapy currently in Phase 1/2 clinical development for the prevention of Graft-versus-Host Disease (GvHD) in patients receiving allogeneic hematopoietic stem cell transplants. Beyond GvHD, ActiTrexx is exploring the application of its Treg platform in various autoimmune diseases where immune tolerance needs to be restored. The company's approach aims to provide a more precise and durable solution compared to traditional broad-spectrum immunosuppressants.